Liver Fibrosis Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Liver Fibrosis Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Report Description

Healthcare professionals focuses on the treatment of liver fibrosis by treating the cause of liver fibrosis, to stops or slows scarring of the liver. Chronic alcohol drinking, autoimmune hepatitis, storage and metabolism disorders such as Wilson disease, Galactosemia, Fructosemia, glycogen storage diseases, iron-overload symptoms, Gaucher disease, some of the bacterial, parasite and viral infections, disorders affecting hepatic blood flow, among others are some of the possible risk factors associated with liver fibrosis management. Furthermore, liver fibrosis treatment market is witnessing increased pace in the NASH treatment.
The underlining prevalence cases of Non-alcoholic Steatohepatitis (NASH) are expected to increase in future with increasing number of population consuming high fat diet. Increasing obesity and diabetes epidemics, liver fibrosis, and NASH are expected to drive market growth, as key players are focused on developing treatment for this disorders.
Market Dynamics
Increasing incidence of liver fibrosis, along with growing prevalence of risk factors such as chronic infection with hepatitis B or C virus, compromised immune system due to co-infection with HIV or use of immunosuppressive drugs after a liver transplant are expected to fuel growth of the liver fibrosis treatment market. Furthermore, growing collaborations and research in order to treat liver fibrosis are expected to spur the liver fibrosis treatment market growth. For instance, in October 2015, professors from University of Newcastle made collaboration with GlaxoSmithKline (GSK) plc to develop drugs, which can stop or reverse liver fibrosis. The aim of collaboration with GSK is to identify existing drugs and develop new compounds, which target myofibroblasts in the treatment of liver fibrosis.
Key features of the study:
This report provides in-depth analysis of liver fibrosis treatment market, its market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year.
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launch or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global liver fibrosis treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Gilead Sciences, Inc., Merck & Co., Inc., Bristol-Myers Squibb, Johnson and Johnson, Novartis AG, Vertex Pharmaceuticals Incorporated, Pfizer Inc., FibroGen, Inc., and Pharmaxis Limited.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future type up-gradation, market expansion, and marketing tactics
The global liver fibrosis treatment market report caters to various stakeholders in this industry including investors, researchers, liver fibrosis treatment drug manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the liver fibrosis treatment market.
Detailed Segmentation:
Global Liver Fibrosis Treatment Market, By Treatment Type:
Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
ACE Inhibitors
Hepatotropic Drug
Others
Global Liver Fibrosis Treatment Market, By Condition:
Chronic Liver Diseases
Hepatitis C
Nonalcoholic Steatohepatitis
Global Liver Fibrosis Treatment Market, By End User:
Hospitals
Specialty Clinics
Retail Pharmacy
Global Liver Fibrosis Treatment Market, By Geography:
North America
By Country:
U.S.
Canada
By Treatment Type:
Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
ACE Inhibitors
Hepatotropic Drug
By Condition:
Chronic Liver Diseases
Hepatitis C
Nonalcoholic Steatohepatitis
By End User:
Hospitals
Specialty Clinics
Others
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Treatment Type:
Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
ACE Inhibitors
Hepatotropic Drug
By Condition:
Chronic Liver Diseases
Hepatitis C
Nonalcoholic Steatohepatitis
By End User:
Hospitals
Specialty Clinics
Others
Asia Pacific
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
By Treatment Type:
Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
ACE Inhibitors
By Condition:
Chronic Liver Diseases
Hepatitis C
Nonalcoholic Steatohepatitis
Hepatotropic Drug
By End User:
Hospitals
Specialty Clinics
Others
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Treatment Type:
Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
ACE Inhibitors
Hepatotropic Drug
By Condition:
Chronic Liver Diseases
Hepatitis C
Nonalcoholic Steatohepatitis
By End User:
Hospitals
Specialty Clinics
Others
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Treatment Type:
Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
ACE Inhibitors
Hepatotropic Drug
By Condition:
Chronic Liver Diseases
Hepatitis C
Nonalcoholic Steatohepatitis
By End User:
Hospitals
Specialty Clinics
Others
Africa
By Country:
North Africa
Central Africa
South Africa
By Treatment Type:
Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
ACE Inhibitors
Hepatotropic Drug
By Condition:
Chronic Liver Diseases
Hepatitis C
Nonalcoholic Steatohepatitis
By End User:
Hospitals
Specialty Clinics
Others
Company Profiles
Gilead Sciences, Inc.*
Company Overview
Product Portfolio
Financial Performance
Recent Developments
Strategies
Merck & Co., Inc.
Bristol-Myers Squibb
Johnson and Johnson
Novartis AG
Vertex Pharmaceuticals Incorporated
Pfizer Inc.
FibroGen, Inc.
Pharmaxis Limited
“*” marked represents similar segmentation in other categories in the respective section.